BridgeBio Pharma, Inc.

BBIO

US10806X1028

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
33.79 ^USD	-0.94%		+16.20%	+23.14%

Jan. 13	BridgeBio Pharma in Strong Cash Position to Launch Attruby	DJ
Jan. 13	BridgeBio Pharma, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 07:30 AM

BridgeBio Pharma Obtains FDA Approval of Attruby

November 25, 2024 at 06:58 am EST

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about BridgeBio Pharma, Inc.

BridgeBio Pharma in Strong Cash Position to Launch Attruby	Jan. 13	DJ
BridgeBio Pharma, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 07:30 AM	Jan. 13
Bayer: CHMP recommends approval of acoramidis	Dec. 13	CF
BridgeBio's Acoramidis Recommended by EU Panel for Transthyretin Amyloid Cardiomyopathy	Dec. 13	MT
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	Dec. 13	CI
BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby	Nov. 26	CI
Health Care Up Amid Cyclical Bias -- Health Care Roundup	Nov. 25	DJ
Sector Update: Health Care Stocks Advance Late Afternoon	Nov. 25	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Nov. 25	MT
Sector Update: Health Care	Nov. 25	MT
BridgeBio Pharma Shares Surge After Obtaining FDA Approval for Attruby	Nov. 25	MT
UBS Adjusts BridgeBio Pharma Price Target to $54 From $47, Maintains Buy Rating	Nov. 25	MT
BridgeBio Pharma Obtains FDA Approval of Attruby	Nov. 25	MT
BridgeBio Pharma, Inc. - Special Call	Nov. 22
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Approves Attruby? for the Treatment of Adults with ATTR-CM	Nov. 22	CI
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia	Nov. 18	CI
BridgeBio Pharma's Q3 Loss Narrows, Revenue Declines	Nov. 12	MT
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q3 Revenue $2.7M	Nov. 12	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 12	CI
Scotiabank Initiates BridgeBio Pharma at Sector Outperform With $44 Price Target	24-10-16	MT
Oppenheimer Initiates BridgeBio Pharma at Perform	24-10-03	MT
BridgeBio Pharma Completes Phase 3 BBP-418 Trial Enrollment	24-09-30	MT
BridgeBio Pharma, Inc. Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)	24-09-30	CI
BridgeBio Pharma, Inc. Presents at 2024 Cantor Fitzgerald Global Healthcare Conference, Sep-17-2024 10:20 AM	24-09-17
Sector Update: Health Care Stocks Steady Premarket Tuesday	24-09-17	MT

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

Employees

553

Sector

Pharmaceuticals

Calendar

2025-02-19 - Q4 2024 Earnings Release (Projected)

More about the company